Standard Chartered PLC (SCBFF) Q2 Earnings and Revenues Surpass Estimates
Standard Chartered PLC (SCBFF) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate…
Standard Chartered PLC (SCBFF) Q2 Earnings and Revenues Surpass Estimates
Standard Chartered PLC (SCBFF) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate…
GSK (GSK) Beats Q2 Earnings and Revenue Estimates
GSK (GSK) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.27…
GSK Discontinues Development of Camlipixant for Refractory Chronic Cough
GSK plc GSK has announced that it is discontinuing development of camlipixant, an investigational P2X3 receptor antagonist, for the…